Sage Journals: Discover world-class research

Abstract

Background

It is unknown whether coagulation properties differ between renal transplant and nontransplant patients.

Objective

To assess whether renal transplant patients on intravenous (IV) heparin, titrated to therapeutic activated partial thromboplastin times (aPPT; 56-93 seconds), experienced a higher rate of bleeding compared to nontransplant patients.

Methods

Twenty-nine renal transplant and 29 nontransplant patients receiving IV heparin for a deep vein thrombosis, pulmonary embolism, atrial fibrillation, or acute coronary syndrome were randomly identified through a retrospective chart review.

Results

Renal transplant patients had higher bleeding rates on IV heparin therapy compared to nontransplant patients (31% vs 6.9%, respectively; P = .041). Renal transplant patients experienced a drop in hemoglobin of at least 1 g/dL or the need for a transfusion more often then nontransplant patients (69% vs 45%, respectively; P = .111), although the difference was not statistically significant.

Conclusions

Further research is necessary to identify the factors contributing to increased rates of bleeding in renal transplant patients on IV heparin and to determine the ideal aPTT to appropriately balance anticoagulation in renal transplant patients.

Keywords

aPTT bleeding heparin renal transplant

Get full access to this article

View all access options for this article.

References

Raschke

Reilly

Guidry

. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Int Med. 1993;119:874–881.

Mathis

Dave

Shah

. Bleeding and thrombosis in high-risk renal transplantation candidates using heparin. Ann Pharmacother. 2004;38:537–543.

Morrissey

Ramirez

Gohh

. Management of thrombophilia in renal transplant patients. Am J Transplant. 2002;2:872–876.

Garcia

Baglin

Weitz

Samama

. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-43s.

Kusyk

Verran

Ryan

. Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttranplantation. Transplant Proc. 2005;37:1026–1028.

Levine

Raskob

Landefeld

. Hemorrhagic complications of anticoagulant therapy. Chest. 1998;114:511S–523S.

Pawlicki

Cierpka

Król

Ziaja

Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation. Transplant Proc. 2011;43(8):3013–3017.

Friedman

Meier-Kriesche

Kaplan

. Hypercoagulable states in renal transplant candidates: Impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation. 2001;72(6):1073–1078.

Bauer

Dreesman

. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: A retrospective cohort study. Mayo Clin Proceed. 2009;84(12):1073–1078.

10.

Landefeld

McGuire

III Rosenlatt

. A bleeding risk index for estimating the probability of major bleeding in hospitalized patient starting anticoagulant therapy. Am J Med. 1990;89(5):569–578.

11.

Sieradzan

Bottner

Fasco

. Comparative effects of cefoxitin and cefotetan on vitamin K metabolism. Antimicrob Agents Chemother. 1988;32(9):1446–1449.

12.

Eng

Brock

. Perioperative anticoagulation and antiplatelet therapy in renal transplant: Is there an increase in bleeding complication? Clin Transplant. 2011;25(2):292–296.